Cue Biopharma, Inc. 宣布与Ascendant Health Sciences Ltd.达成一项独家授权协议，获得一款临床阶段双机制抗IgE抗体的全球权益。此举标志着该公司产品管线的战略性扩展。
该抗体药物采用创新的双重作用机制，旨在更有效地治疗由免疫球蛋白E（IgE）介导的过敏性疾病。目前，该候选药物已进入临床开发阶段，展现出潜在的治疗优势。
通过此次授权合作，Cue Biopharma进一步丰富了其在免疫学领域的研发组合。公司计划加速推进该抗体的临床开发，为患有相关疾病的患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.